Tempus AI news

Stock broke out on Thursday, suggesting positive technical momentum and investor interest.

Stock surged 39.5% this week on validation of its pending Personalis acquisition through successful Merck-Moderna trial results. The acquisition is positioned to provide strong tailwinds for Tempus's precision medicine and genomic diagnostics growth strategy.

Company demonstrated strong operational momentum with 22% Q2 revenue growth to $382.5 million, achieved its first GAAP profit, and is acquiring Personalis to enhance genomic sequencing capabilities. The pending $1.5 billion Personalis acquisition positions the company well in precision medicine, particularly following the Moderna-Merck vaccine trial success. Despite being down 10% over the past year, recent execution and stock rally suggest positive trajectory.

Company demonstrated strong fundamentals with 22% revenue growth, achieved first GAAP profit, and stock rallied 75% following validation of its genomic sequencing technology by Moderna-Merck trial results. However, still unprofitable on TTM basis and insider's non-discretionary sale during rally suggests caution about valuation levels.

The data segment led by Fukushima demonstrated strong 28% YoY growth with $93.2 million in revenue and $200 million in new data and application licenses signed. The Insights product grew 36%, indicating robust business momentum in a high-margin segment that is less dependent on lab volume or reimbursement rates. The insider's substantial remaining stake (624,000 shares) demonstrates continued confidence in the company.

Stock price fell from $52.47 to $46.05 following announcement of Personalis acquisition; deal structure includes floating exchange ratio which negatively impacts Personalis shareholders

The company faces legal scrutiny regarding potential conflicts of interest in its acquisition of Personalis. Its preexisting ownership position and strategic relationship raise concerns about whether the acquisition process was conducted fairly and at arm's length.

Despite the CEO's share sale, the article emphasizes strong fundamentals including 20% YoY revenue growth, 31% oncology volume growth, and a strategic $1.5 billion acquisition of Personalis targeting a $20 billion market opportunity. The CEO's retention of 6.5 million shares demonstrates continued alignment with shareholders. The sale is characterized as routine portfolio management rather than a loss of confidence.

The article highlights Tempus AI's strong growth potential through its healthcare data platform, AI tools, FDA progress, and pharmaceutical partnerships. The stock is positioned as a potential AI winner in the healthcare sector with meaningful upside opportunities.

The company is expanding its partnership with a major pharmaceutical company, demonstrating growing adoption of its AI platform (Lens) for clinical trial optimization. This represents business growth and validation of its technology in drug development.

Stock price jumped 7.30% on positive news regarding 31 accepted abstracts at AACR meeting showcasing advances in AI-driven oncology research and biomarker discovery. However, sentiment is tempered by Jefferies' concurrent Underperform rating and $35 price target, suggesting mixed analyst outlook despite positive near-term market reaction.

Announced a significant multi-year strategic collaboration with Merck to enhance precision medicine discovery and development. The partnership demonstrates confidence in Tempus' AI capabilities and data infrastructure, and is expected to support Merck's oncology portfolio. Recent quarterly results also beat revenue estimates.

Listed among prominent participants in the competitive landscape. Positioned to benefit from increasing adoption of AI-powered real-world evidence integration and treatment outcome analysis.

Stock gained 32.4% over the past month with strong revenue growth of 21.6% year-over-year and improving profitability trajectory (EPS loss narrowing from -$0.22 to -$0.04).

Key player in AI-enabled oncology and real-world data integration for blood cancer therapeutics.

Mentioned as acquirer but not subject of investigation; no direct allegations against the company

Cited as a precedent (~$9B market cap) demonstrating that proprietary biological data paired with AI commands premium public-market valuation. Brad Keywell's involvement as Infinite's board chairman is highlighted as validation, but the mention is primarily comparative rather than sentiment-driven.

Referenced as example of scaled AI diagnostics platform with reimbursement pathways. Demonstrates investor appetite for AI-enabled diagnostics but operates at much larger scale and broader scope than Ventripoint.

Rose 9.4% alongside other healthcare-AI stocks as precision-diagnostics sector rallied.

Tempus' AI-enabled analytical platform (Lens) is being integrated into the Bristol-Myers Squibb collaboration, providing validation of its technology and expanding its role in clinical trial optimization.

Highlighted as a well-watched commercial success story with strong 2025 revenue ($1.2B) and 2026 guidance ($1.59B) projecting first year of positive adjusted profitability, demonstrating institutional investor appetite for AI medical platforms.

Company is building a valuable recurring data platform with network effects in precision medicine; 83% revenue growth in 2025 to $1.27B and $1B+ in contract value demonstrate strong market traction and scalability potential.

Mentioned as an active partnership with Pathos AI but no new developments or changes to the partnership are disclosed in this announcement.

Highlighted for strategic acquisition of Deep 6 AI in March 2025 to enhance patient recruitment and AI-driven trial matching capabilities, demonstrating active market expansion.

31.34% weekly gain following commercial expansion announcement with Predicta Biosciences for genomic sequencing

Reported 83% YoY Q4 2025 revenue growth ($367.2M), full-year 2025 revenue of $1.2B, and 2026 guidance of $1.59B with projected first year of positive adjusted profitability ($65M adjusted EBITDA).

Revenue of $367.21M beat Street estimate of $362.29M, though losses of 4 cents per share were in line with consensus.